Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health Study.
| Title: | Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health Study. |
|---|---|
| Authors: | Kraus D; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Gieswinkel A; Preventive Cardiology and Preventive Medicine - Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Boedecker-Lips SC; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Klimpke P; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Stortz M; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Schleicher EM; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Schattenberg JM; Department of Internal Medicine II, Saarland University Medical Centre, Homburg, Germany.; Pfeiffer N; Department of Ophthalmology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Ghaemi J; Department of Psychosomatic Medicine and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Schmidtmann I; Institute for Medical Biometry, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Lackner KJ; Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Tüscher O; Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Institute of Molecular Biology (IMB), Mainz, Germany.; Münzel T; Department of Cardiology - Cardiology I, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Wild PS; Preventive Cardiology and Preventive Medicine - Center for Cardiology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Institute of Molecular Biology (IMB), Mainz, Germany.; Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; German Center for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Mainz, Germany.; Galle PR; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Weinmann-Menke J; I. Department of Medicine, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.; Center of Immunotherapy Mainz (FZI), Johannes Gutenberg University Mainz, Mainz, Germany. |
| Source: | Clinical kidney journal [Clin Kidney J] 2025 Dec 22; Vol. 19 (2), pp. sfaf399. Date of Electronic Publication: 2025 Dec 22 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101579321 Publication Model: eCollection Cited Medium: Print ISSN: 2048-8505 (Print) Linking ISSN: 20488505 NLM ISO Abbreviation: Clin Kidney J Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Oxford : Oxford University Press |
| Abstract: | Background: Early diagnosis of chronic kidney disease (CKD) is essential to slow progression and delay or prevent dialysis. However, in the absence of specific symptoms, patients and physicians may remain unaware of the disease for a long period. Here we present an analysis from the Gutenberg Health Study, a prospective longitudinal cohort study, to estimate the prevalence of CKD indicators in the population.; Methods: A representative sample of 10 125 individuals underwent extensive medical testing at baseline; 9331 were tested again after 5 years. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration formula with serum creatinine. Urinary albumin:creatinine ratios (UACRs) were determined from spot urine samples.; Results: At baseline, 2.5% of subjects had decreased eGFR (30 mg/g) and 1.0% had both. Within 5 years, the incidence of new-onset decreased eGFR was 3.4%, the incidence of new-onset increased albuminuria was 6.9% and 1.4% had both new-onset decreased eGFR and increased albuminuria. Most importantly, 6.8% of all subjects and 3.2% of subjects without hypertension, diabetes or known kidney disease had chronic increased albuminuria, consistent with the presence of CKD.; Conclusions: This is the first study to report the longitudinal prevalence of CKD in the population. Chronic increased albuminuria, a sensitive marker of CKD, is highly prevalent in the German population even in the absence of risk factors for kidney disease.; (© The Author(s) 2025. Published by Oxford University Press on behalf of the ERA.) |
| Competing Interests: | J.M.S. declares consultant honoraria outside the submitted work from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kríya Therapeutics, Lilly, MSD Sharp & Dohme, Nordic Bioscience, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers, Summit Clinical and Vantage Biosciences Research; speaker honoraria from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen Novo Nordisk, Madrigal Pharmaceuticals and Worldwide Clinical Trials and stockholder options from Hepta Bio. P.S.W., outside the submitted work, declares consulting fees from AstraZeneca. research funding from Bayer AG; research funding, consulting and lecturing fees from Bayer Health Care; lecturing fees from BMS; research funding and consulting fees from Boehringer Ingelheim; research funding and consulting fees from Daiichi Sankyo Europe; consulting fees and non-financial support from Diasorin; non-financial research support from I.E.M.; research funding and consulting fees from Novartis Pharma; lecturing fees from Pfizer Pharma; non-financial grants from Philips Medical Systems; and research funding and consulting fees from Sanofi-Aventis. He is principal investigator of the future cluster ‘curATime’ (BMBF 03ZU1202AA, 03ZU1202CD, 03ZU1202DB, 03ZU1202JC, 03ZU1202KB, 03ZU1202LB, 03ZU1202MB, and 03ZU1202OA) and principal investigator of the DIASyM research core (BMBF 161L0217A) and the DZHK (German Center for Cardiovascular Research), Partner Site Rhine-Main, Mainz, Germany. D.K. and and J.W.M. declare honoraria outside the submitted work from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, and CSL Vifor. |
| Contributed Indexing: | Keywords: chronic kidney disease; disease progression; increased albuminuria; population health; prevention |
| Entry Date(s): | Date Created: 20260327 Date Completed: 20260327 Latest Revision: 20260327 |
| Update Code: | 20260327 |
| PubMed Central ID: | PMC13014362 |
| DOI: | 10.1093/ckj/sfaf399 |
| PMID: | 41890981 |
| Database: | MEDLINE |
Journal Article